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1. Introduction 
1.1. Definition and structure of Neuregulin-1 (Nrg1) 
Hypothalamus-derived dopamine and thyrotrophin-releasing hormone (TRH) have long 
been considered the main sources of prolactin (PRL) regulators in the anterior pituitary, 
whereas other substances also modulate PRL expression and secretion (Borrelli et al., 1992; 
Cai et al., 1999; Spuch et al., 2006). Recently, Vlotides for the first time observed that 
recombinant Nrg1 can control PRL secretion from rat RPL and growth hormone (GH) 
secreting lactosomatotroph GH3 cells, suggesting the emerging role of Nrg1 as a PRL 
regulator (Vlotides et al., 2009).  
Neuregulins are homologous to epidermal growth factor (EGF) and are mainly encoded by 
four alternatively spliced genes: NRG-1 to -4 (Orr-Urtreger et al., 1993). Diverse splicing of 
the NRG-1 gene gives rise to at least six main types of Nrg1 (types I–VI) with ectodomain 
variation, whereas type I to III Nrg1. are the most intensively investigated. All types of Nrg1 
contain an EGF-like domain, which can be classified as either α or β (Jacobsen et al., 1996; 
Rosnack et al., 1994). Distinct from soluble Nrg1, a membrane-tethered Nrg1 precursor has 
been identified that contains a transmembrane (TM) domain and an intracellular domain 
(ICD). The ICD can be further characterized as ICD a, b and c. The structure that links the 
ectodomain and the transmembrane (TM) domain is called a stalk (S), which can be further 
classified as S1, S2 and S4. Proteolysis of the Nrg1 precursor, a tightly regulated process, 
releases the soluble domains and leads to formation of autocrine⁄paracrine loops. However, 
recruitment of S3, which contains the stop codon, terminates the extension of the 
ectodomain into the cytoplasm and thus leads to the formation of non-membrane anchored 
Nrg1α/β (See Fig 1).  
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Figure 1. Schematic of type I- III Nrg1 Diverse splicing of NRG-1 gene gives rise to Type I-III Nrg1s, 
whose structures were schematically diagrammed. α, EGF-like domain α; β, EGF-like domain β; Ig, Ig-
like domain; s, stalk domain; sp, spacer domain.   
1.2. Interaction of Nrg1 with its cognate receptors and related biological 
functions 
The bioactivity of Nrg1 is mainly mediated by homodimers comprised of their cognate 
receptors ErbB4 (Hahn et al., 2006) or ErbB3/ErbB2 and ErbB4/ErbB2 heterodimeric 
complexes (Liu et al., 2002) (See Fig 2). Nrg1 was found to specifically activate the tyrosine 
kinase receptor ErbB2 as a growth factor extracted from the conditioned medium of a 
human breast tumor cell line (Holmes et al., 1992). It exerts mitogenic activity on cultured 
Schwann cells as type II Nrg1 (Glial growth factor, GGF) purified from the brain and bovine 
pituitary anterior lobe (Lemake et al., 1984). The acetylcholine receptor-inducing activity 
protein (ARIA), another Nrg1 type, was shown to promote acetylcholine receptor synthesis 
in cultured skeletal muscle and myotubes (Jessell et al., 1979; Usdin et al., 1986). The ligand-
receptor interaction initiates a complex intracellular signaling cascade in which extracellular 
signal-regulated kinase (ERK), serine/threonine protein kinase (AKT), mitogen-activated 
protein kinase (MAPK), phosphatidyl-inositol 3-kinase γ (PIK3γ), protein kinase C (PKC), 
and Janus kinase-signal transducers and activators of transcription (Jak-STAT) are activated. 
Activation of this signaling pathway leads to, among other events, tumorigenic 
development, cell cycle arrest, cell proliferation, differentiation, and anti-apoptotic processes 
(Peles et al., 1993; Liu and Kern et al., 2002; Puricelli et al., 2002). Recently, Nrgβ1 has been 
reported to signal mitogenesis of cortical astrocytes through ErbB1⁄ErbB3 heterodimeric 
complex (Sharif et al., 2009).  
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Figure 2. Schematic of type I- III Nrg1 interaction with their receptors. The initial proteolysis site was 
indicated by the arrow, and the site for second proteolysis was indicated by the arrow head. 
2. Endogenous expression of Nrg1 in the anterior pituitary and rat 
lactosomatotroph GH3 cells 
2.1. Expression and localization of Nrg1 and its receptor in the anterior pituitary 
of rat and non-human primates 
The Nrg1-ErbB signaling pathway has a critical role in organ development, cell 
differentiation and tumorigenesis. Neuregulins have previously been described in the 
nervous system, especially in the cortex, spinal cord and hypothalamus. In the 
hypothalamus, ARIA (or Nrg1α and β) was expressed in neurons with processes projecting 
to the posterior pituitary gland but not in those without these projections, suggesting that 
hypothalamus-derived Neuregulin regulates certain functions of the pituitary (Bernstein et 
al., 2006; Corfas et al., 1995). Furthermore, Nrg1 receptors were reported to be expressed in 
hypothalamic astrocytes, where their activation as a result of paracrine Nrg1 stimulation is 
essential for stimulating secretion of luteinising hormone-releasing hormone (LHRH), 
intrapituitary gonadotrophin secretion and normal sexual puberty (Bernstein et al., 2006; 
Prevot et al., 2003).  
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Neuregulin has also been reported to be expressed in the endocrine organs, including the 
adrenal gland and the adult pancreas (Harari et al., 1999; Orr-Urtreger et al., 1993). 
Additionally, thyroid-derived cell lines and corresponding papillary carcinomas also 
express Nrg1 and ErbB receptors ErbB2 and ErbB4 (Fluge et al., 2000; Mincione et al., 1998). 
By contrast, Nrg1 expression and localization, as well as its role in the adenohypophyseal 
structure, have not been fully defined for a long time. Recently, exogenous Nrg1 has been 
reported to modulate PRL mRNA expression and PRL secretion from the rat 
lactosomatotroph GH3 cells, where the ErbB3 receptor was shown to correlate with 
malignant transformation of prolactinomas (Vlotides et al., 2009). Thus, it is essential to 
elucidate (i) whether the anterior pituitary gland endogenously expresses Nrg1, (ii) whether 
intrahypophyseal Nrg1⁄ErbB receptor can regulate PRL secretion and (iii) its relevance to the 
development of prolactinoma. 
2.1.1. Multiple Nrg1 isoforms are expressed in the anterior pituitary and GH3 cells 
Based on a domain RT-PCR method systematically used by Cote et al. (2005), multiple 
isoforms of Nrg1 were amplified. In our work, we first amplified a 392-bp band from the rat 
cortex and anterior pituitary cDNA, corresponding to the spacer domain (SP)-containing Ig-
EGFα segment in type I Nrg1 (Fig 3A). When primers spanning the Ig-like domain and the 
EGFβ domain were used, a band at 401 bp was amplified from the cortex, hypothalamus 
and anterior pituitary cDNA, representing type I Nrg1β. A 299-bp band was amplified from 
the cortex and hypothalamus, but not from the anterior pituitary cDNA, which represents 
the SP free Ig- EGFβ segment exclusively contained in type II Nrg1 (Fig 3B). With primers 
specific to both the Ig domain and S1, S3 or S4, we found that S1 and S3 are present in type I 
Nrg1 in rat cortex, hypothalamus and anterior pituitary (Fig 3C-E). When primers against 
the CRD-EGFα domain was employed, an 833-bp band was weakly amplified from the 
cortical cDNA and strongly amplified from the anterior pituitary and GH3 cells (Fig 3G). 
Using primers against the CRD-EGFβ domain, an 842-bp band was amplified in all tested 
samples (Fig 3H ). With primers specific to CRD and S1, S3 or S4, we found that S1 and S3 
are present in both forms of type III Nrg1 in rat cortex, hypothalamus, anterior pituitary and 
GH3 cells (Fig 3I, J), whereas S4 was present in rat cortex and undetectable in the other 
samples tested (Fig 1K). GAPDH signals were equal in each group, suggesting the equal 
loading of samples (Fig 3F). To confirm the expression of membrane-anchored Nrg1, 
transmembrane segments were amplified by using primers specific to the different types of 
cytoplasmic domains. All samples tested showed two similar bands, in which the upper 
band represents the TM-cytoplasmic a tail segment and the lower band represents the TM-
cytoplasmic b tail segment (Fig 3L).  
By contrast to previous studies depicting type II Nrg1 (GGF I-III) expression in the pituitary 
(Goodearl  et al., 1993), other studies do not support this idea as a result of the absence or 
extremely low levels of GGF mRNA in rat pituitary with in situ hybridization (ISH) or RT-
PCR (Marchionni et al., 1993). In line with the letter, the rat anterior pituitary expresses both 
type I Nrg1α⁄ β and type III Nrg1α⁄ β, whereas the GH3 cells only express type III Nrg1α⁄ β 
(Tab 1). This suggests that Nrg1 may have specific functions there. Furthermore, the 
 
Neuregulin-1 (Nrg1): An Emerging Regulator of Prolactin (PRL) Secretion 87 
presence of both membrane-tethered Nrg1 and soluble Nrg1 may function in an autocrine ⁄ 
paracrine manner. 
 
Type sample α β S1 S3 S4 ICD-a ICD-b ICD-c 
I AP + + + + - + + + 
 GH3 - - - - - - - - 
II AP - - - - - - - - 
 GH3 - - - - - - - - 
III AP + + + + - + + + 
 GH3 + + + + - + + + 
Table 1. Nrg1 domain identification in the anterior pituitary (AP) and GH3 cells (GH3) based on 
domain RT-PCR. α, EGF-like domain α; β, EGF-like domain β; S, stalk domain; ICD, intracellular 
domain.  
 
Figure 3. Domain RT-PCR for multiple Nrg1 isoforms in the rat cortex, hypothalamus, anterior 
pituitary and GH3 cells. Reverse transcriptase-PCR with several sets of domain specific primers 
amplified the expression of Nrg1 isoforms in the hypothalamus (HP) and anterior pituitary (AP) and 
GH3 cells (GH3). Rat cortex (Cor) serves as positive control. D-Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used to indicate the equal loading of samples. The schematic diagrams 
right to the RT-PCR results indicate domains that the RT-PCR products contain. α, EGF-like domain α; 
β, EGF-like domain β; s, stalk domain; CRD, cysteine-rich domain; ICD, intracellular domain; TM, 
transmembrane domain. (Zhao et al., 2011a) 
At the protein level based on Western blot, the anterior pituitary give rise to a group of 
bands with a wide range of molecular weights as a result of alternative splicing and post-
translational modification such as hyperglycosylation. In the anterior pituitary cell lysates, 
bands at 140, 110, 95 and 90 kDa, representing the main Nrg1 precursors, were observed, 
whereas, in the hypothalamus cell lysates, a weak band at 110 kDa was observed. Soluble 
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Nrg1s at 36 and 30 kDa were detected in the anterior pituitary, whereas only the 36 kDa 
Nrg1 was detected in the hypothalamus. 
In the anterior pituitary, Nrg1α⁄β was co-localized with Nrg1α, further confirming the 
domain RT-PCR and western blotting results and indicating that Nrg1α is the predominant 
intrapituitary Nrg1. However, Nrg1α⁄β was not co-localized with S-100, GH and ACTH, 
which serve as markers for folliculo-stellate cells, somatotrophs and corticotrophs, 
respectively. Notably, neighbouring localization of Nrg1 with PRL was observed, 
suggesting a potential interaction between lactotrophs and Nrg1 positive cells. In addition, 
Nrg1 was weakly detected in partial PRL positive lactotrophs. Further 
immunofluoresecence investigation demonstrated Nrg1α⁄β were co-stained with FSH or LH, 
both of which are markers for gonadotrophs. Significant co-localization of Nrg1α⁄β with 
either FSH or LH was noted in the transition zone between pars tuberalis and pars distalis. 
However, in the pars distalis, such co-localization was relatively weak. This suggests that 
gonadotrophs in the pars tuberalis adjacent to the pars distalis are the major source of 
intrapituitary Nrg1α/β (Fig 4) (Zhao et al., 2011a). 
 
Figure 4. Gonadotrophs are the main source of Nrg1 in the anterior pitutiary. PL, posterior lobe; IL, 
intermediate lobe; AL, anterior lobe. A, pars tuberalis; B, pars distalis. (Zhao et al., 2011a) 
In addition, RT-PCR demonstrated varying expression patterns of Nrg 1 isoforms at the 
mRNA level during the estrous cycle. Type I Nrg1α was expressed at a low level during the 
proestrous (PE) phase and at a constant level in other phases. In contrast, low levels of type I 
Nrg1β were observed in the metestrous (ME) and diestrous (DE) phases. Type II Nrg1 was 
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expressed at the highest level during the E1 phase. Both type III Nrg1α and type III Nrg1β 
were expressed at higher levels during the E1 and E2 phases, when an estrogen surge 
occurred in response to hypophyseal gonadotrophic hormones. At the protein level, the 
expression of both 110 kDa and 95 kDa Nrg1s in the anterior pituitary were significantly 
higher in E1 and E2 phases. No similar expression pattern was observed in the posterior 
pituitary (Zhao et al., 2011c). In spite of these observations, it is still unclear whether Nrg1 
functions in an sex-dependent manner or not in the anterior pituitary, and unfortunately, 
little is known about the sex-specific expression and function of Nrg1 in the brain (Taylor et 
al., 2012). 
2.1.2. Localization of Nrg1 and ErbB4 receptor in the anterior pituitary of male Rhesus 
monkeys 
In male Rhesus monkeys aged 5-7 years, the existence of Nrg1 and ErbB4 was observed, 
which showed a partial adjacent pattern, suggesting the existence of Nrg1/ErbB4 juxtacrine 
signaling in the anterior pituitary in non–human primates (See Figure 5) (Zhao et al., 2011c).  
 
Figure 5. Nrg1 and ErbB4 receptor are expressed in the anteior pituitary of the rhesus monkey. The 
anterior pituitary of Rhesus monkey was subjected to immunofluorescence staining for both Nrg1 and 
ErbB4 (Green: Nrg1; Red: ErbB4; Blue: DAPI).  
2.2. Expression and Localization of Nrg1 in GH3 cells 
Exogenous Nrg1 was first shown to increase PRL mRNA expression and PRL secretion from 
GH3 cells by activating the ErbB3 receptor and intracellular AKT. In addition, the ErbB3 
receptor has been shown to correlate with the malignant transformation of prolactinomas 
(Vlotides et al., 2008, 2009).  
Subsequent investigation demonstrated that administration of siRNA against Nrg1 reduced 
the expression of multiple isoforms, including the 110-, 60-, 36-, 33-, and 30-kDa proteins, 
indicating that these bands potentially represented alternatively spliced Nrg1 gene 
 Prolactin 90 
products, post-translationally modified forms, and/or the shed ectodomains from their 
initial precursors. Immunofluorescence staining also demonstrated the reduced expression 
of Nrg1α/β in GH3 cells. Nrg1 was detected, with the ErbB2 receptor partially expressed in 
some human prolactinoma samples. This suggests the existence of Nrg1/ErbB receptor 
autocrine/paracrine signaling during the development of prolactinoma. 
In addition, type III Nrg1 (SMDF) is distinct from the other two types of Nrg1 and contains 
an extra N terminal transmembrane structure. In type III Nrg1, initial proteolysis frees the 
EGF-like domain from the membrane, leading to juxtacrine signalling characterised by 
reciprocal intercellular communication (Bao et al., 2003; Hancock et al., 2008). Further 
cleavage releases a shorter EGF-like domain-containing peptide, which functions in 
autocrine ⁄ paracrine interactions. Indeed, high levels of ErbB4 receptor and Nrg1 have also 
been reported to be expressed in K-ras transformed thyroid Kimol and A6 cells, where Nrg1 
signals through the ErbB2/ErbB4 heterodimeric complex in an autocrine manner (Mincione 
et al., 1998). Although Nrg mRNA was present in both tumor and non-tumor tissue, Nrg 
precursor isoform immunohistochemically showed nuclear immunostaining in most human 
papillary carcinomas but not in normal thyroid tissue. Cytoplasmic Nrgα, β1 and β3 were 
also exclusively detected in papillary carcinomas (Fluge et al., 2000). Significant expression 
of the ErbB2, ErbB3 and ErbB4 receptors, in addition to Nrg1 isoforms, was also detected in 
the developing murine fetal pancreas, where they potentially contribute to islet 
development and regrowth (Kritzik et al., 2000). The strong expression of Nrg1 in 
lactosomatotroph GH3 tumor cells was in sharp contrast with that observed in the anterior 
pituitary, where Nrg1 was almost undetectable in the prolactotroph (Zhao et al., 2011b). 
Thus, overexpression of Nrg1 may play a vitally functional role in prolactinoma 
development. 
3. Autocrine/juxtacrine modulation of prolactin (PRL) secretion via 
Nrg1/ErbB receptor pathway 
3.1. Modulating role of Nrg1 on PRL secretion in the anterior pituitary 
Previous studies have described the morphological relationship between prolactotrophs and 
gonadotrophs, which is characterised by conditional gap junctions, and have reported the 
functional roles of LH on PRL secretion in response to GnRH (Andries et al., 1995; Denef et 
al., 1983). More recently, Henderson et al. (2008) described GnRH-induced PRL release 
independent of gonadotrophins.  
FSH positive gonadotrophs can form contacts with ErbB3 positive cells and ErbB3 was also 
shown to be localized on the prolactotroph membrane. These observations, altogether, 
raised the hypothesis that Nrg1 present in gonadotrophs may function by modulating 
lactotrophs by interacting with ErbB3 receptor on the membrane. Thus, intrapituitary 
gonadotrophs and prolactotrophs may partially use gap junctions to form contacts, allowing 
the binding of gonadotroph-derived membrane-tethered type III Nrg1 to ErbB3 receptors on 
the prolactotrophic membrane. In addition, both prolactotrophs and gonadotrophs may 
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form contacts through cell adhesion molecules widely distributed in the anterior pituitary, 
including L1 cell adhesion molecule and neural cell adhesion molecule (Zhao et al., 2010). 
These molecules may increase the interaction between Nrg1 and ErbB receptors, such as 
ErbB3 and ErbB4, a process that may activate a series of intracellular signals and also 
increase enzymatic cleavage of the PRL precursor.  
In one study, type I and type III Nrg1α⁄β as well as membrane-tethered type III Nrg1 were 
able to be identified using domain-specific primers-based RT-PCR in the mouse 
gonadotroph αT3-1 cells. Using Western blot assays with an anti-Nrg1 antibody, a cluster of 
proteins were observed with molecular weights in the range 30–114 kDa. Proteins at 70, 60 
and 45 kDa were also detected in serum-free culture medium conditioned by αT3-1 cells. 
However, commonly recognized soluble Nrg1 with molecular weight ranging from 40–25 
kDa were rarely observed, suggesting the precursor is the main form of Nrg1 in this 
gonadotroph cell line, which may be the base for juxtacrine interaction between Nrg1 and its 
cognate receptors. Subsequently, PRL and GH secreting GH3 cells were co-cultured with 
gonadtroph αT3-1 cells pretreated with siRNA against Nrg1. Administration of siRNA 
against mouse Nrg1 significantly reduced the staining intensities of intracellular Nrg1α⁄β, as 
well as their co-localization, as observed with immunofluorescence assays. Nrg1 reduction 
in αT3-1 cells reduced PRL expression in co-cultured GH3 cells. Co-culturing of GH3 cells 
with αT3-1 cells treated with siRNA against Nrg1 significantly reduced the secretion of an 
18 kDa form of PRL from GH3 cells at 48 h, although it had no significant effect on the 
secretion of 23-kDa PRL and 22-kDa GH. This result, coupled with the observation that 
membrane-tethered type III Nrg1 is mainly expressed in the gonadotrophs, suggests the 
existence of a type III Nrg1-mediated juxtacrine mechanism that affects secretion of a subset 
of PRL, a process that may also occur in the normal anterior pituitary. 
Cleaved full-length PRL has been reported to be a vascular function modulator mainly in 
the 16-kDa form (Clapp et al., 2006, 2008; Macotela et al., 2006). However, an 18- kDa form 
was also reported as an intermediate form of the final cleavage product in vitro (Lkhider et 
al., 2004; Nicoll et al., 1997). We reported that Nrg1 can modulate the release of an 18-kDa 
cleavage form of PRL, which is typical to GH3 cells. This process may be related to the 
modulation of Nrg1 on enzymes specific for PRL cleavage, such as cathepsin D and matrix 
metalloprotease (MMP) family members (Clapp et al., 2006, 2008; Macotela et al., 2006). 
Indeed, Nrg1 has been shown to promote the expression of MMP-7 and -9 in an ErbB 
receptor dependent manner in cancer cells (Ueno et al., 2008; Yuan et al., 2006). 
3.2. Modulating role of Nrg1 on PRL secretion in rat   lactosomatotroph GH3 
cells 
In one study, siRNA method was used to investigate the autocrine/paracrine effect of Nrg1 
on PRL secretion. siRNA of Nrg1 significantly downregulated the release of a soluble form 
of 36 kDa Nrg1 into the conditioned culture medium. Western blotting analysis showed 
significantly reduced secretion of both the 23-kDa and the 18-kDa PRLs into the conditioned 
culture medium in response to the reduced secretion of 36 kDa Nrg1, and a reduction in 
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ErbB3 receptor activation was also observed. However, downregulation of Nrg1 has no 
effects on GH secretion. Thus, Nrg1 may modulate PRL secretion from GH3 cells in an 
autocrine, paracrine/juxtacrine manner (See Fig 6). 
 
Figure 6. Schematic diagram illustrating the hypothesized model for Neuregulin-1 (Nrg1) on PRL 
regulation. A, autocrine; P, paracrine; J, juxtacrine. 
4. Nrg1/ErbB receptor inhibition as a potential clinical management of 
prolactinoma 
The role of Nrg1-mediated autocrine, paracrine, or juxtacrine signaling in several aspects of 
cancer biology suggests that it is a potential target for tumor therapy. Success with a 
combined therapeutic antibody and sheddase inhibitor treatment has been demonstrated in 
the mammary cancer MCF- 7 cell line, in which the administration of INCB7839 (a second 
generation sheddase inhibitor) with Lapatinib prevents the growth of ErbB2 positive BT474-
SC1 human breast cancer xenografts in vivo (Witters et al., 2008). Gefitinib, a tyrosine kinase 
inhibitor, has also been reported to suppress Nrg1-mediated ErbB2/ErbB3 signaling to PRL 
(Vlotides et al., 2008, 2009). A recent investigation has also revealed that Lapatinib, an ErbB2 
inhibitor, possesses additional effects in the suppression of PRL expression, and oral 
Lapatinib treatment triggers the shrinkage of estrogen-induced prolactinomas in rats 
(Fukuoka et al., 2010). Thus, the co-localization of Nrg1 with ErbB2 in partial prolactinomas 
suggests that inhibiting Nrg1 expression or abolishing its binding ability might also have 
similar effects in inhibiting Nrg1-dependent ErbB receptor activation and prolactinoma 
progression. In one of our studies, five human prolactinoma tissues were stained for both 
Nrg1 and ErbB2. All samples demonstrated positive staining for Nrg1, and co-expression of 
both molecules was observed in one sample (Zhao et al., 2011b). Additional prolactinoma 
samples should be recruited to stress further the role of Nrg1/ErbB receptor singling in 
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future investigations. The findings regarding the endogenous expression of Nrg1 and an 
Nrg1-mediated autocrine/paracrine mechanism in GH3 cells have expanded previous 
results and reveal Nrg1 as a potential diagnostic serological marker for prolactinoma. In 
addition, a therapeutic approach involving the direct functional inhibition of Nrg1 might be 
a viable clinical treatment for PRL-secreting pituitary tumors. 
5. Conclusions and perspectives 
Among a series of regulators of PRL, the emerging role of Nrg1 is rather new, but important. 
Overexpression of Nrg1 and its cognate receptor ErbB2, as well as their co-localization 
provides the promising therapeutic method to control prolactinoma and 
hyperprolactinemia. Such a clinical purpose can be achieved by 1) Nrg1 receptor inhibitor, 
such as Erlotinib, Lapatinib et al.; 2) neutralizing antibody against Nrg1 and 3) their 
combination. Additionally, Nrg1-mediated autocrine/paracrine mechanism in GH3 cells 
have expanded previous results and reveal Nrg1 as a potential serological marker not only 
for prolactinoma diagnosis, but for prognosis evaluation post operation. In addition, a 
therapeutic approach involving the direct functional inhibition of Nrg1 might be a viable 
clinical treatment for PRL-secreting pituitary tumors. To avoid the side effects, such as 
affecting the physiological function of circulating Nrg1 brought by intravenous 
administration of anti-Nrg1 antibody, the therapeutic hypothesis may be established by 
intratumoral (i.t.) injection of the therapeutic antibody in patients, whose prolactinomas are 
highly resistant to chemotherapy or in whom the tumor location can lead to high surgery 
risk.  It has recently been reported that experimental i.t. injections with ErbB2 targeted gold 
nanoparticles (AuNPs) resulted in high tumor retention with low systemic exposure and 
represents an attractive delivery strategy (Chattopadhyay et al., 2012). 
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